Ingrezza could have some advantages over approved therapies, but a more important Huntington’s readout nears.
While Lilly has thrown in the tau towel with zagotenemab, Cortexyme still sees reasons to press on with atuzaginstat.
But mixed data and a previous failure provide reasons to be cautious.
The group’s purchase of Affiris’s Parkinson’s portfolio comes after stumbles from Roche/Prothena and Biogen.
The failure of gosuranemab could bode ill for Abbvie’s ABBV-8E12 in particular.
Prilenia’s pridopidine is the last big late-stage hope in the disorder, but it already failed phase 2, and phase 3 under the name Huntexil.
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
The next big approach in Alzheimer’s has been dealt a blow, and there are plenty more tau-targeting contenders.